Purpose: A novel transdermal formulation of granisetron (the granisetron transdermal delivery system (GTDS)) has been developed to deliver granisetron continuously over 7 days. This double-blind, phase III, non-inferiority study compared the efficacy and tolerability of the GTDS to daily oral granisetron for the control of chemotherapy-induced nausea and vomiting (CINV).
Patients And Methods: Six hundred forty-one patients were randomized to oral (2 mg/day, 3-5 days) or transdermal granisetron (one GTDS patch, 7 days), before receiving multi-day chemotherapy. The primary endpoint was complete control of CINV (no vomiting/retching, no more than mild nausea, no rescue medication) from chemotherapy initiation until 24 h after final administration. The prespecified non-inferiority margin was 15%.
Results: Five hundred eighty-two patients were included in the per protocol analysis. The GTDS displayed non-inferiority to oral granisetron: complete control was achieved by 60% of patients in the GTDS group, and 65% in the oral granisetron group (treatment difference, -5%; 95% confidence interval, -13-3). Both treatments were well tolerated, the most common adverse event being constipation.
Conclusions: The GTDS provides effective, well-tolerated control of CINV associated with moderately or highly emetogenic multi-day chemotherapy. It offers a convenient alternative route for delivering granisetron for up to 7 days that is as effective as oral granisetron.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3166600 | PMC |
| http://dx.doi.org/10.1007/s00520-010-0990-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mirtazapine plus granisetron and dexamethasone for carboplatin-induced nausea and vomiting in patients with thoracic cancers: A prospective multicenter phase II trial.
Lung Cancer
June 2024
Department of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, Gifu 501-1194, Japan; Laboratory of Advanced Medical Pharmacy, Gifu Pharmaceutical University, 1-25-4 Daigakunishi, Gifu, Gifu, 501-1196, Japan. Electronic address:
Article Synopsis
- Mirtazapine, when combined with granisetron and dexamethasone, was studied for preventing nausea and vomiting caused by carboplatin in patients with thoracic cancers.
- A trial involving 52 patients showed high rates of complete response—83.3% during the delayed phase (24-120 hours) and 100% in the acute phase (0-24 hours)—with minimal side effects.
- Results suggest that this three-drug combination is effective and safe for patients undergoing chemotherapy with carboplatin at specified dosages.
Olanzapine for the prevention of postoperative nausea and vomiting after gynecologic laparoscopic surgery: a randomized controlled trial.
Ther Adv Drug Saf
April 2024
Department of Critical Care Medicine, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, No. 150, Ximen Street, Taizhou 317000, China.
Article Synopsis
- This study looked at how well olanzapine, a medication, prevents nausea and vomiting after certain surgeries in women.
- 250 patients were tested, with some taking olanzapine and others taking a placebo (fake pill) before surgery.
- Results showed that only 8.3% of patients taking olanzapine felt nauseous or vomited compared to 19.2% of those who took the placebo, meaning olanzapine helped reduce these problems.
Effect of Selective 5-Hydroxytryptamine-3 Receptor and Neurokinin-1 Receptor Antagonists on Hemodynamic Changes and Arrhythmogenic Potential in Patients Receiving Chemotherapy: A Retrospective, Observational Study.
J Clin Med
February 2024
Department of Medical Oncology, Ankara Gazi University, Ankara 06500, Turkey.
Prior speculation suggests that selective 5-hydroxytryptamine-3 receptors and neurokinin-1 receptor antagonists may increase arrhythmia risk and induce electrocardiographic changes. This study examined the effect of anti-emetic medications on arrhythmogenic potential and hemodynamic alterations. We considered patients aged 18 or above receiving chemotherapy between June 2013 and December 2013.
View Article and Find Full Text PDFPharmacological Treatments of Temporomandibular Disorders: A Systematic Review Including a Network Meta-Analysis.
Drugs
January 2024
Division of Oral Diagnostics and Rehabilitation, Department of Dental Medicine, Karolinska Institutet, Box 4064, SE-14104, Huddinge, Sweden.
Objective: Temporomandibular disorders (TMD) comprise a cluster of conditions with a wide range of etiological factors that causes pain and discomfort in the masticatory muscles (TMD-M) and temporomandibular joints (TMD-J). More than 50% of the patients with TMD report regular usage of drugs. However, there is still no consensus, nor is there any evidence-based support for clinicians when choosing between different drugs.
View Article and Find Full Text PDFSerotonin 3 receptor antagonists for obsessive-compulsive disorder: A systematic review and pairwise meta-analysis.
J Psychiatr Res
November 2023
Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, 470-1192, Japan.
Article Synopsis
- A systematic review and meta-analysis were conducted to evaluate the effectiveness of serotonin 3 receptor antagonists (5-HT3R-As) in treating obsessive-compulsive disorder (OCD) by analyzing data from 10 double-blind, randomized, placebo-controlled trials involving 628 participants.
- * The analysis showed that 5-HT3R-As significantly improved the overall OCD symptoms (measured by the Yale-Brown Obsessive Compulsive Scale), including both obsession and compulsion scores when compared to placebo.
- * Despite these positive outcomes, there were no significant differences in treatment discontinuation or adverse event rates between 5-HT3R-As and placebo, indicating the need for further studies with larger sample sizes to confirm these findings
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!